GB Patent

GB9716557D0 — Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity

Assigned to Glaxo Group Ltd · Expires 1997-10-08 · 29y expired

What this patent protects

Patent listed against dabrafenib-mesylate.

Drugs covered by this patent

dabrafenib-mesylate (DABRAFENIB MESYLATE)

Patent Metadata

Patent number: GB9716557D0
Jurisdiction: GB
Classification: —
Expires: 1997-10-08
Drug substance claim: No
Drug product claim: No
Assignee: Glaxo Group Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.